AMENDMENT TO RULES COMMITTEE PRINT 118–36

OFFERED BY MS. SLOTKIN OF MICHIGAN

At the end of subtitle B of title VII, add the following:

SEC. 7___. REPORT ON PREFERENCE FOR PHARMACEUTICAL AGENTS MANUFACTURED IN THE UNITED STATES.

(a) IN GENERAL.—Not later than 180 days after the date of enactment of this Act, the Secretary of Defense, in consultation with other administering Secretaries (as such term is defined in section 1072 of title 10, United States Code), shall submit to the congressional defense committees a report evaluating the effect of preferencing pharmaceutical agents manufactured in the United States when determining the inclusion of a pharmaceutical agent in the uniform formulary under the pharmacy benefits program established under section 1074g of title 10, United States Code.

(b) CONTENTS.—The report required under subsection (a) shall include the following:

(1) A description of any criteria the Secretary of Defense uses to determine the inclusion of a phar-

maceutical agent in the uniform formulary under the pharmacy benefits program that is not required under section 1074g(a)(2)(A) of title 10, United States Code.

(2) A description of how, if at all, the Secretary of Defense preferences pharmaceutical agents manufactured in the United States when determining the inclusion of a pharmaceutical agent in the uniform formulary under the pharmacy benefits program.

(3) An evaluation of the costs, benefits (including with respect to reducing reliance on foreign pharmaceutical supply chains by the Department of Defense), and other impacts of statutorily requiring the DoD to preference pharmaceutical agents manufactured in the United States when determining the inclusion of a pharmaceutical agent in the uniform effects under the pharmacy benefits program.